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This study aimed to define the most consistent white matter (WM) microarchitecture pattern in 
Parkinson's disease (PD) reflected by fractional anisotropy (FA), addressing clinical profiles and 
methodology-related heterogeneity. Web-based publication databases were searched to conduct a 
meta-analysis of whole-brain diffusion tensor imaging studies comparing PD patients with healthy 
controls (HC) using the anisotropic effect size–signed differential mapping. A total of 808 PD 
patients and 760 HC coming from 27 databases were finally included. Subgroup analyses were 
conducted considering heterogeneity with respect to medication status, disease stage, analysis 
methods and the number of diffusion directions in acquisition. Compared with HC, PD patients 
had decreased FA in the left middle cerebellar peduncle, corpus callosum, left inferior fronto-
occipital fasciculus and right inferior longitudinal fasciculus. In subgroup meta-analyses of 
medicated patients, early stage patients, voxel-based analysis and acquisition with ˂ 30 diffusion 
directions, most of the main results remained unchanged. The subgroup meta-analysis of 
medication-free patients showed FA decrease in the right olfactory cortex. The cerebellum and 
corpus callosum, associated with the typical motor impairment, showed the most consistent FA 
decreases in PD. Medication status, analysis approaches and the number of diffusion directions 
have an important impact on the findings, needing careful evaluation in future meta-analyses.  
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Parkinson's disease (PD) is the second most common neurodegenerative disease [1]. Clinically, 
PD is characterized by progressive motor symptoms such as bradykinesia, rigidity, resting tremor 
and postural instability, and various non-motor symptoms [2]. The pathophysiology of PD has yet 
to be fully elucidated and there are no preventative or curative treatments. Recently, 
psychoradiology (https://radiopaedia.org/articles/psychoradiology) is emerging as the study of 
brain diseases through a variety of non-invasive imaging techniques. Diffusion tensor imaging 
(DTI), a widely used magnetic resonance imaging (MRI) technique to visualize and measure the 
diffusion of water, is particularly useful because of its high sensitivity to changes in white matter 
(WM) integrity [3]. Fractional anisotropy (FA), the most commonly used DTI parameter, is 
positively associated with WM anisotropy, and can detect microstructural abnormalities of WM at 
very early stages [4, 5].  
Many DTI studies of PD have identified decreased FA in various brain regions, including corpus 
callosum [6-9], cerebellum [8, 10-12], and superior and inferior longitudinal fasciculus [9, 10], but 
others have found no significant FA differences between PD patients and healthy controls (HC) 
[13-15]. These discrepancies may be attributable to factors such as small or heterogeneous study 
samples and methodological differences. To gain insight into the pathophysiology a meta-analysis 
has a better chance of detecting consistent regions of FA alterations in PD. 
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Earlier reviews and meta-analyses confirmed that symptoms of PD are a result of degeneration of 
the substantia nigra [16-18]. Although the pathologic process is mainly attributed to disruptions in 
the nigrostriatal dopamine system, previous neuroimaging studies in PD have focused on the 
substantia nigra using a seed-point method. By examining pre-defined regions of interest, some 
important cerebral alterations may have been missed. To overcome region placement preference 
bias, we chose a widely-used whole-brain method to analyze the WM changes in PD. Previous 
DTI meta-analyses [19] did not directly test the hypothesis of WM changes in PD patients 
compared with HC, and confounding factors such as medication status, disease stage and 
methodological differences were not fully considered. A comprehensive meta-analysis is needed 
to explore the WM microstructure abnormalities and to investigate the effects of symptom severity 
and other clinical characteristics on regional WM alterations.  
The aim of this meta-analysis was to define the most consistent WM microstructural changes, 
reflected by FA, in PD patients using published whole brain DTI studies. To reduce the effects of 
heterogeneity, several subgroup analyses were conducted. Meta-regression analyses were used to 
evaluate the influence of clinical and demographic characteristics.  
Materials and Methods 
Data sources, study selection, and quality assessment 
This retrospective study was approved by the local institutional review committee. In accordance 
with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
statement [20], a comprehensive search of studies published before May 14th 2018, was conducted 
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in the PubMed, Web of Science, and Embase databases using the keywords “Parkinson” OR 
“Parkinson’s disease” OR “PD”; AND “diffusion tensor” OR “diffusion tensor imaging” 
OR“ DTI”. The references of these studies and relevant review articles were checked for additional 
relevant studies. Studies that satisfied the following conditions were included in the meta-analysis: 
(i) patients were diagnosed with idiopathic PD; (ii) FA was compared between patients and HC; 
(iii) three-dimensional coordinates (Montreal Neurological Institute [MNI] or Talairach) were 
reported for the whole-brain FA analysis; (iv) significant results were reported using thresholds 
for significance corrected for multiple comparisons or uncorrected with spatial extent thresholds; 
and (v) the study was published as an original article (not as a letter or abstract) in a peer-reviewed 
English-language journal. Datasets were excluded if they explicitly included patients diagnosed 
with comorbid neurological or psychiatric diseases (e.g. cognitive impairment or depression) [21]. 
To avoid sample overlaps: (1) for longitudinal studies, only baseline data were included [21]; (2) 
for studies reporting both on- and off-state results, only off-state datasets were included [21]; (3) 
for multiple studies using the same patient group, only the largest sample was included. Finally, 
the meta-analysis included 27 datasets from 24 studies with 808 PD patients (429 men and 379 




Figure 1. Flowchart describing study selection for the meta-analysis. 
Two of the authors independently rated each included study for quality and completeness using a 
12-point checklist adapted from previous published meta-analyses [22] (Table S1), any 
discrepancies being resolved by a third investigator.  
Voxel-wise meta-analysis 
We analyzed FA differences in WM between patients with PD and HC using anisotropic effect 
size–signed differential mapping (AES-SDM) (www.sdmproject.com), a voxel-based meta-
analytic approach (See Supplementary Material). As detailed elsewhere [23-25], we extracted peak 
coordinates and effect sizes (e.g. t-values) of FA differences between PD patients and HC from 
each dataset. For each dataset, we recreated a standard MNI map of FA differences using an 
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anisotropic Gaussian kernel, from which the mean map was generated by voxel-wise calculation, 
weighted by sample size, intra-dataset variability, and between-dataset heterogeneity. To optimally 
balance false positive and negative findings, we used the default SDM kernel size and thresholds 
(full width at half maximum [FWHM] = 20 mm, uncorrected p = 0.005 was used as the main 
threshold, peak height Z = 1, cluster extent = 10 voxels) [23, 24]; this FWHM kernel is intended 
to assign indicators of proximity to reported coordinates but not to smooth any image that is 
different in nature [25]. To allow the combination of VBA and TBSS studies, we adopted the 
TBSS template included in AES-SDM [26]. We used MRIcron software 
(http://www.cabiatl.com/mricro/mricron/) to visualize AES-SDM maps overlaid onto a high-
resolution brain image template created by the International Consortium for Brain Mapping.  
Jackknife sensitivity analysis 
Following preprocessing, we performed a whole-brain voxel-based jackknife sensitivity analysis 
to test the robustness of the findings by iteratively repeating the analysis, excluding one dataset 
each time. If a brain region remains significant in all or most of the combinations of studies, the 
finding is considered highly replicable [23]. 
Analyses of heterogeneity and publication bias 
We conducted a heterogeneity analysis using a random effects model with Q statistics to explore 
unexplained between-study variability in the results: heterogeneous brain regions were obtained 
using the default SDM kernel size and thresholds [25]. We also performed Egger’s test for 
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publication bias by extracting the values from statistically significant relevant peaks between PD 
patients and HC [27]. 
Subgroup analyses 
Several subgroup meta-analyses were conducted to analyze clinical and methodological 
differences between these studies. This subgroup analysis included only studies with defined 
clinical and methodological homogeneity, and was conducted for studies that investigated 
medicated and medication-free (including both medication-naïve and off-state) patients, studies 
that investigated early stage (Hoehn and Yahr [H&Y] stage 1-2.5) patients [28], studies where the 
number of acquisition diffusion directions was ≥ 30 and ˂ 30 [29], and studies that used VBA or 
TBSS approaches. 
Meta-regression analyses 
We used meta-regression analyses to examine the effects of age, percentage of female patients, 
illness duration, H&Y stage, Unified Parkinson's Disease Rating Scale (UPDRS) Part III score, 
and levodopa equivalent daily dose (LEDD) of the PD patients. We decreased the probability 
threshold to 0.0005 and cluster extent = 10 voxels, as described previously [26]. Regression plots 




Included studies and sample characteristics 
The meta-analysis included 24 studies [6-15, 30-43] and 3 of them included 2 independent 
databases [8, 13, 15], resulting in 27 datasets in all. Table 1 summarizes the demographic, clinical, 
and imaging information of these studies, which provided a total of 41 coordinates of altered FA 
in patients with PD versus HC. Ten datasets from 8 studies and 11 datasets from 10 studies 
explicitly indicated patients in the medication off-state and on-state, and 1 studies included 
medication-naïve patients. Five studies did not provide any information about the medication 
status (on- or off-state) at DTI acquisition. The patients recruited in 6 datasets from 5 studies were 
at their early stage. The number of acquisition diffusion directions was ≥ 30 in 11 datasets from 
10 studies, and ˂ 30 in 16 datasets from 14 studies. Seventeen studies used the TBSS approach, 5 
used VBA, 1 used whole-brain-based spatial statistics and 1 used grey-matter-based spatial 
statistics. Five of the 25 studies were performed on 1.5T scanners and 19 on 3T scanners. The 
quality scores, ranging from 9.5 to 12 (mean 10.7), demonstrated that the included studies were of 
high quality (Table 1).  
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66.66 60.19 22.46 1.69 0.55 Drug-naïve - 3.0T 64 FSL TBSS p˂0.05, 
TFCE corr 
0 10.5 




63.8 66.0 19.1 ˂4 7.4 On-state 689 3.0T 32 FSL VBA p˂0.01, 
TFCE corr 
0 12 




61.9 57.9 NA 1-1.5 ≤5 On-state NA 3.0T 60 FSL TBSS p˂0.05, 
TFCE corr 
0 11.5 




63.6 63.6 16.3 2.2 6.0 On-state 748 3.0T 30 FSL TBSS p˂0.001, 
uncorr 
0 10.5 





























67.6 66.5 16.1* 2.1 6.4 On-state NA 3.0T 32 FSL GBSS p˂0.05, 
TFCE corr 
2 11.5 











52.55 54.46 22.27 1.63 2.35 Off-state 305 3.0T 25 FSL TBSS p˂0.05, 
TFCE corr 
0 11 













55.1 58.1 28.9 1.94 4.87 Off-state 249 3.0T 61 FSL TBSS p˂0.05, 
TFCE corr 
0 10.5 




64.20 59.95 32* 2* 5* Off-state NA 3.0T 30 FSL TBSS p˂0.05, 
TFCE corr 
1 11 













67.6 68.1 32.5 2.5* 7.6 On-state 461 3.0T 25/40/75 FSL TBSS p˂0.05, 
FDR corr 
3 11.5 




63.9 64.0 28.3 2.4 10.0 On-state 567 1.5T 12 FSL TBSS p˂0.05, 
TFCE corr 
0 9.5 













67* 66* 26# NA 4* NA NA 1.5T 12 TIFT WBSS p˂0.05, 
FDR corr 
1 9.5 











65 64 40.92 3.46 12.38 Off-state NA 1.5T 12 FSL TBSS p˂0.05, 
TFCE corr 
0 9.5 




71.6 72.7 NA 2.4 7.83 On-state 464* 3.0T 32 FSL TBSS p˂0.05, 
TFCE corr 
0 10.5 




62.9 63.0 NA 2* 5.3 Off-state NA 3.0T 15 FSL TBSS p˂0.05, 
TFCE corr 
0 9.5 




64.0 70.1 25.3 2* 3.7 On-state 208 3.0T 28 FSL TBSS p˂0.05, 
TFCE corr 
0 11 




75.9 76.9 20 2.7 5.8 NA NA 1.5T 12 FSL TBSS p˂0.05, 
TFCE corr 
0 9.5 

















PD, Parkinson’s disease; HC, healthy controls; UPDRS, unified Parkinson's disease rating scale; H&Y, Hoehn and Yahr stage; NA, not available; LEDD, 
levodopa equivalent daily dose; SPM, statistical parametric mapping; FSL, functional MRI of the brain (FMRIB) software library; TBSS, tract-based spatial 
statistics; VBA, voxel-based analysis; TFCE, threshold-free cluster enhancement; FDR, false discovery rate; corr, corrected; uncorr, uncorrected; 1, patients with 
tremor-dominant; 2, non-tremor-dominant; 3, patients without hyposmia; 4, patients with freezing of gait; 5, without freezing of gait; 6, early and mild patients; 7, 
moderate and severe patients; * Median; #, UPDRS. 
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FA differences in the main meta-analysis 
The meta-analysis revealed decreased FA in patients with PD relative to HC, in the left middle 
cerebellar peduncles (MCP), corpus callosum (CC), left inferior fronto-occipital fasciculus, and 
right inferior longitudinal fasciculus (Figure 2, Table 2).  
 
Figure 2. Regions showing reduced fractional anisotropy in patients with Parkinson’s disease 
compared with healthy controls. CC, corpus callosum; IFOF, inferior fronto-occipital fasciculus; 




Table 2. Regional FA differences between patients with PD and HC identified by the present meta-analysis. 







voxels Cluster breakdown (no. voxels) 
Egger’s test   
(p value) x y z 
L middle cerebellar peduncles -32 -54 -42 -1.412 0.000098109 221 Middle cerebellar peduncles (84) 0.107 
L cerebellum, crus I (9) 
L cerebellum, hemispheric lobule VIIB (7) 
L cerebellum, hemispheric lobule VIII (7) 
L cerebellum, crus II (5) 
L cerebellum, hemispheric lobule VI (1) 
undefined (108) 
L corpus callosum -22 -62 34 -1.754 ~0 87 Corpus callosum (66) 0.122 
L superior longitudinal fasciculus II (11) 
L superior longitudinal fasciculus I (4) 
L inferior parietal (excluding 
supramarginal and angular) gyri, BA 7 (3) 
L middle occipital gyrus, BA 7 (3) 
L inferior network, inferior 
fronto-occipital fasciculus 
-36 -20 -4 -1.164 0.000784993 59 L inferior network, inferior fronto-
occipital fasciculus (43) 
0.126 
undefined, BA 48 (12) 
undefined, BA 20 (4) 
R corpus callosum 26 -60 32 -1.251 0.000539660 29 Corpus callosum (29)  0.059 
R inferior network, inferior 
longitudinal fasciculus 
40 -58 -4 -1.204 0.000637770 16 R inferior network, inferior longitudinal 
fasciculus (12) 
0.057 
Right inferior temporal gyrus, BA 37 (4) 
BA, Brodmann area; FA, fractional anisotropy; HC, healthy controls; L, left; MNI, Montreal Neurological Institute; 





Jackknife sensitivity analysis 
Whole-brain jackknife sensitivity analysis showed that the most robust results were obtained for 
FA decreases in the WM regions of the left MCP and left CC, which were preserved throughout 
all combinations; right inferior longitudinal fasciculus and right CC were relatively replicable, 
being preserved throughout all but one combination; FA decreases in the left inferior fronto-
occipital fasciculus remained significant in all but two combinations (Table 3). 
Table 3. Jackknife sensitivity analysis*. 








Left inferior network, 
inferior fronto-
occipital fasciculus 
Right inferior network, 
inferior longitudinal 
fasciculus 
Guan et al. (2018)[30] Yes Yes Yes Yes Yes 
Wen et al. (2018)[31] Yes Yes Yes Yes Yes 
Peran et al. (2018)[32] Yes Yes Yes Yes Yes 
Rektor et al. (2018)[33] Yes Yes Yes Yes Yes 
Acosta-Cabronero et al. 
(2017)[34] 
Yes Yes Yes Yes Yes 
Chen B et al. (2017)[6] Yes Yes Yes Yes Yes 
Chen MH et al. (2017)[11] Yes Yes Yes Yes Yes 
Chiang et al. (2017)[10] Yes Yes No No No 
Kamagata et al. (2017)[42] Yes Yes Yes No Yes 
Luo et al. (2017) a[13] Yes Yes Yes Yes Yes 
Yes Yes Yes Yes Yes 
Zanigni et al. (2017)[35] Yes Yes Yes Yes Yes 
Vervoort et al. (2016)[36] Yes Yes Yes Yes Yes 
Ji et al. (2015)[7] Yes Yes Yes Yes Yes 
Vercruysse et al. (2015) a[8] Yes Yes Yes Yes Yes 
Yes Yes Yes Yes Yes 
Agosta et al. (2014)[37] Yes Yes Yes Yes Yes 
Worker et al. (2014)[14] Yes Yes Yes Yes Yes 
Rosskopf et al. (2014)[43] Yes Yes Yes Yes Yes 
Agosta et al. (2013) a[15] Yes Yes Yes Yes Yes 
 Yes Yes Yes Yes Yes 
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Kamagata et al. (2013)[38] Yes Yes Yes Yes Yes 
Kim et al. (2013)[39] Yes Yes Yes Yes Yes 
Melzer et al. (2013)[40] Yes Yes Yes Yes Yes 
Hattori et al. (2012)[41] Yes Yes Yes Yes Yes 
Zhang et al. (2011)[12] Yes Yes Yes Yes Yes 
Kendi et al. (2008)[9] Yes Yes Yes Yes Yes 
Total 27 out of 27 27 out of 27 26 out of 27 25 out of 27 26 out of 27 
a, two datasets included. 
*“Yes” indicates that the specific region of FA reduction was significant in the specific jackknife analysis; “No” 
indicates that the specific region of FA reduction was not significant in specific analysis. 
Analyses of heterogeneity and publication bias 
The left CC with altered FA had significant statistical heterogeneity among studies (p < 0.005; 
Table 4). Egger’s tests for publication bias were not significant with respect to FA differences in 
the left MCP (p = 0.107), left CC (p = 0.122), left inferior fronto-occipital fasciculus (p = 0.126), 
right CC (p = 0.059), or right inferior longitudinal fasciculus (p = 0.057) (Table 2). 
Table 4. Regions of FA heterogeneity from the SDM analysis. 
Brain region MNI coordinates SDM z score P value 
(uncorrected) 
No. voxels Cluster 
breakdown 
 x y z    (no. voxels) 
Corpus callosum -26 -62 32 1.911 0.000073612 12 Corpus callosum 
(12) 




The medication-free subgroup (comprising off-state [n = 10 datasets] and medication-naïve [n = 1 
datasets]) included 11 datasets comprising 374 patients with PD and 328 HC. The analysis revealed 
FA decreases in the right olfactory cortex. The medicated group (n =13 datasets) comprised 340 
patients with PD and 347 HC. The main results remained unchanged. We then used a threshold of 
LEDD = 400 mg/day to defined two medicated subgroups. In the LEDD ˂ 400 mg/day subgroup 
analysis [n = 5 datasets], comprising 205 patients with PD and 144 HC, the main results remained 
unchanged; by contrast the LEDD ≥ 400 mg/day subgroup [n = 8 datasets], comprising 142 
patients with PD and 177 HC, revealed FA increases in the bilateral CC.  
In the early stage disease (n = 6 datasets) and VBA (n = 5 datasets) subgroups, the main results 
remained unchanged, but the TBSS (n = 20 datasets) subgroup analysis failed to detect between-
group differences. In the ˂ 30 diffusion directions subgroup analysis (n = 16 datasets), four of the 
main results remain unchanged, while the ≥ 30 diffusion directions subgroup (n = 11 datasets) only 
revealed one main result in the left inferior fronto-occipital fasciculus. Detailed results of 
subgroups analyses are shown in Table 4, Figure S1-S6. 
Table 4. Subgroup meta-analysis of studies in PD patients compared with HC. 
 
Brain region 










x y z 
Medication-free 
patients 
R olfactory cortex, BA 48 22 12 -18 -1.156 0.000049055 50 
Medicated patients L middle cerebellar peduncles -34 -54 -44 -1.645 0.000296830 65 
 L corpus callosum -24 -62 28 -1.647 0.000220776 61 
 L inferior network, inferior fronto-occipital fasciculus -36 -20 -4 -1.662 0.000196218 54 
 R corpus callosum 24 -60 32 -1.645 0.000269830 31 
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 R inferior network, inferior longitudinal fasciculus 42 -58 -6 -1.630 0.000318885 17 
LEDD ≥ 400mg R corpus callosum 4 -14 26 1.122 0.000049055 146 
 L corpus callosum -22 -38 28 1.060 0.000343442 65 
LEDD ˂ 400mg L middle cerebellar peduncles -30 -54 -38 -1.496 0.000073612 71 
 R corpus callosum 28 -62 28 -1.495 0.000073612 31 
 L corpus callosum -20 -62 32 -1.457 0.000392497 23 
 L inferior network, inferior fronto-occipital fasciculus -34 -20 -2 -1.486 0.000171721 21 
 R inferior network, inferior longitudinal fasciculus 44 -54 -6 -1.481 0.000269830 12 
Early stage patients L middle cerebellar peduncles -34 -58 -38 -1.473 0.000024557 76 
 R corpus callosum 22 -60 34 -1.467 0.000098109 31 
 Left middle occipital gyrus, BA 7 -30 -68 38 -1.458 0.000196218 30 
 L corpus callosum -20 -60 34 -1.465 0.000122666 20 
 L inferior network, inferior fronto-occipital fasciculus -36 -20 -4 -1.445 0.000269830 15 
 R inferior network, inferior longitudinal fasciculus 42 -64 -6 -1.458 0.000196218 12 
TBSS None       
VBA L middle cerebellar peduncles -40 -56 -38 -2.350 ~0 263 
 L corpus callosum -28 -64 26 -2.341 ~0 97 
 R corpus callosum 24 -58 30 -1.721 0.000515163 24 
 L inferior network, inferior fronto-occipital fasciculus -36 -20 -4 -1.667 0.001030266 12 
 Right inferior network, inferior longitudinal 
fasciculus 
44 -56 -6 -1.702 0.000662327 10 
Number of diffusion directions ≥30       
 Left inferior network, inferior fronto-occipital 
fasciculus 
-36 -14 -10 -1.133 0.000073612 66 
Number of diffusion directions <30       
 L middle cerebellar peduncles -32 -54 -42 -1.682 0.000024557 224 
 L corpus callosum -28 -62 28 -1.683 0.000024557 87 
 R corpus callosum 26 -60 30 -1.357 0.000343442 29 
 R inferior network, inferior longitudinal fasciculus 40 -56 -4 -1.334 0.000539660 16 
 Left inferior network, inferior fronto-occipital 
fasciculus 
-36 -20 -4 -1.023 0.002551138 10 
BA, Brodmann area; HC, healthy controls; L, left; MNI, Montreal Neurological Institute; PD, Parkinson’s disease; 




The mean age of patients, percentage of women with PD (in the whole PD group in each study), 
mean illness duration, mean H&Y stage, mean UPDRS-III score, or mean LEDD of patients with 
PD were not significantly associated with PD-related WM FA changes, at least linearly. 
Discussion 
The main abnormalities and their potential significance 
Our pooled meta-analysis of DTI studies revealed significant WM microarchitecture alterations in 
patients with PD compared to HC, indicated by the decreased FA values. There was consistent FA 
decrease in the left MCP, CC, left inferior fronto-occipital fasciculus, and right inferior 
longitudinal fasciculus. Jackknife sensitivity analysis, heterogeneity analysis and Egger's tests 
confirmed the robustness of these findings. Although the subgroup analysis of medication-free 
patients did not reveal decreased FA as in the main analysis, it detected an additional cluster in the 
right olfactory cortex. Meta-regression analyses revealed no significant association between WM 
alterations and relevant demographic and clinical variables.  
Given the role of the MCP as the main afferent pathway from the cortex to the cerebellum, and 
additional findings of diffusion changes in brainstem and pons [44], these data emphasize the role 
of the cortico-ponto-cerebellar loop in PD pathology. It contains afferent axons from the pontine 
nuclei [45] and mediates complex brain functions concerning movement and cognition. PD 
features motor dysfunction such as tremor, rigidity, bradykinesia, gait disturbance and postural 
instability [46]. Studies in patients with freezing of gait found WM abnormalities in the pontine-
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cerebellar tracts [8, 47, 48] which might explain their reduced ability to recruit the cerebellum. 
Functional studies in PD found hypoactivation in the cerebellum during a motor task [49]. This 
neurodegeneration in MCP is consistent with the critical role of cerebellum for motor performance 
[46, 50]. Moreover, the subgroup analysis of PD patients with early stage disease detected 
decreased FA in MCP, an area with a significant decline in diffusivity in early PD, correlating with 
motor progression [51]. 
Being the largest WM bundle in human brain, the CC connects the bilateral cerebral hemispheres 
[52], so this finding, suggesting hemispheric involvement [53], is consistent with resting-state 
studies reporting decreased interhemispheric functional connectivity in PD [54-56]. In previous 
DTI studies in PD, altered FA was reported in different subdivisions of the CC, such as the genu, 
usually associated with cognitive impairment [37, 38, 57]. Microstructural impairment of CC has 
been reported in cognitively normal PD patients, which points towards an affected 
interhemispheric connectivity that possibly shapes the onset of cognitive deficits [58]. In our meta-
analysis abnormal microstructure of the posterior CC was detected in both the pooled analysis and 
the subgroups of patients with early stage disease, medicated patients, VBA method and ˂ 30 
diffusion directions; this is consistent with reports of a smaller posterior CC volume in PD patients 
[59]. Transcallosal motor fiber bundles were found to cross the corpus callosum in the posterior 
part [60]. The anatomic projections found in this study are compatible with previous observations 
that CC abnormalities are related to postural instability and freezing of gait in PD [60], which 
becomes more severe with motor worsening [61]. Thus, the importance of neurodegeneration of 
CC in PD is also reflected through its role in motor features of the disease. 
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The inferior longitudinal fasciculus is an associative bundle connecting the occipital and temporal 
lobes. Its long fibers connect visual areas to the amygdala and hippocampus, the main components 
of the limbic system related to emotional behavior [62]; it is involved in face recognition [63], 
visual perception [64], and visual memory [65]. The inferior fronto-occipital fasciculus is a ventral 
associative bundle connecting the ventral occipital lobe and the orbitofrontal cortex [66]. Its 
occipital component runs parallel to the inferior longitudinal fasciculus. On approaching the 
anterior temporal lobe, its fibers gather together and enter the external capsule dorsally to the 
fasciculus. It is involved in reading [67] and visual processing [68]. The functions of these two 
bundles are not yet completely understood in PD. Guan and colleagues found that the inferior 
longitudinal fasciculus was associated with motor impairment and global disease severity in PD 
[30], which has been also reported in relation to the tremor-dominant (TD) subtype of PD, 
indicating probably different underlying pathology between TD and other motor subtypes [69]. FA 
values in the inferior fronto-occipital fasciculus were negatively correlated with bradykinesia of 
PD [70], and it may be that disruption of this structure might contribute to freezing of gait due to 
impaired visuospatial processing [71]. However, a recent DTI study showed significant differences 
in these two bundles between patients with postural instability gait disorder and HC [72]. The role 
of these two bundles in differentiating white matter changes in PD motor subtypes requires further 
investigation. Notably, previous studies also found relationships between these two bundles and 
non-motor symptoms of PD, e.g. depression [73] and cognitive dysfunction [74]. Although studies 
with comorbid depression and cognitive dysfunction were excluded in the current meta-analysis, 
the potentially confounding effects cannot be completely ruled out. Although detailed depression 
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scales were not used in these included studies, it is known that depression is a frequent non-motor 
symptom of PD patients, and its prevalence can be as high as 90% [75]. 
Meta-analyses have been carried out on DTI studies in PD [17]. Although these earlier meta-
analyses provide valuable insights into the underlying white matter pathology, differences in the 
region of interest (ROI) placement likely result in significant heterogeneity between studies. 
Relative to ROI-based analyses, coordinate-based analyses are less susceptible to errors relating 
to the lack of spatial distinction [76]. There is relatively poor consistency of results between the 
previous ROI meta-analyses and our current coordinate-based meta-analysis, and this has 
implications for neuroimaging meta-analyses of other disorders, such as amnestic mild cognitive 
impairment [76] and posttraumatic stress disorder [77]. Several factors might contribute to these 
differences. First, ROI studies typically report on a subset of brain regions and are likely to suffer 
from publication bias. Second, where seed-based d mapping uses coordinate data, the effect size 
is biased toward zero in brain regions where there are no significant clusters. 
Subgroup analyses 
The subgroup analysis of medication-free patients detected a cluster in the right olfactory cortex, 
which is considered an early affected site in the Braak model of temporal degeneration in PD [78]. 
A recent DTI study suggested that olfactory regions were particularly efficient at distinguishing 
drug-naïve PD patients from HC [79]. There is evidence of a strong link between olfactory 
discrimination and orbitofrontal cortex [80]. Decreased FA in the olfactory cortex may be related 
to the olfactory dysfunction which is present in ~90% of early stage PD [81]. However, we did not 
observe this alteration in olfactory cortex in the pooled whole-group results. The reason for this 
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discrepancy is unclear, although it could be that changes associated with medication may 
normalize, or at least obscure, the intrinsic changes in these regions. Medication exposure is an 
important potential confounder and understanding the effect of medications on white-matter 
abnormalities in patients with PD is critical for the interpretation of results. In functional MRI 
studies, levodopa has generally been reported to normalize altered functional connectivity in PD 
[82]. Medications have been also shown to affect cerebral WM, e.g. benztropine used in the 
treatment of tremor in PD promote re-myelination [83]. In the current meta-analysis, the main 
results of LEDD ˂ 400 mg/day subgroup analysis remain unchanged, while the results of the 
LEDD ≥ 400 mg/day subgroup showed increased FA in the bilateral CC, sharing these 2 clusters 
with the results of the pooled meta-analysis. This observation seems to fit a ‘normalization’ effect. 
Although other diffusion MRI studies have shown that medication per se has little influence on 
WM integrity or does not alter diffusion [38, 84], nevertheless, the effect of dopaminergic 
medication on WM are still unclear. The differential influence of dopamine medication is likely 
determined by additional factors. Inter-individual differences and disease severity should also be 
considered. Further studies are needed specifically designed to detect the effect of medication 
exposure on WM changes in patients with PD. 
Scan acquisition parameters also affect the FA measurements individually and in group 
comparisons. The minimum requirement for a qualitative DTI calculation is 6 non-collinear 
diffusion directions, while robust estimation of FA and tensor orientation requires at least 30 
unique and evenly distributed sampling orientations [29]. DTI studies with less than 30 diffusion 
directions tends to overestimate FA values, which might affect group-wise differences. However, 
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our subgroup analysis of ≥ 30 diffusion directions showed the same robust FA decrease in left 
inferior fronto-occipital fasciculus as in the main analysis. Nevertheless, future DTI meta-analyses 
should consider the number of diffusion directions. 
Subgroup analysis of the VBA studies revealed clusters that were identified in the pooled analysis; 
however, the subgroup analysis of the TBSS studies did not. This may be a methodological issue. 
TBSS was developed to analyze diffusion data, and it isolates the central core of WM tracts with 
the highest FA and reports significant clusters within that WM skeleton [85]; however, it may miss 
abnormalities in the peripheral WM [86]. VBA investigates the integrity of all WM voxels, 
including peripheral regions of WM and fiber crossings [87]. Differences in findings between the 
two methods are thus to be expected. Moreover, given the small number of VBA studies (n = 5), 
we cannot completely rule out the possibility of chance findings.  
Limitations of this study 
First, methodological heterogeneity cannot be completely excluded: it was impossible to perform 
analyses or subgroup analyses of all relevant variables. Second, the medication-free patients of 
subgroup meta-analysis were mostly medicated patients in the off-state at scanning. Clearly, the 
best way to minimize the effects of treatment is to study medication-naïve patients; however, this 
subgroup was small. Moreover, results of the subgroup meta-analysis for medication-free datasets 
should be interpreted with caution, considering the possible methodological differences between 
the studies, e.g. diffusion directions and analysis methods. Third, as is inherent in all coordinate-
based methods, our meta-analysis used the coordinates from the included studies rather than the 
original t-statistic maps, which somewhat limits the accuracy of the results. Fourth, although we 
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performed several subgroup meta-analyses for the early stage, VBA and different LEDD 
medicated datasets, the results should be interpreted with caution. The small sample size of these 
subgroup meta-analyses limit the generalizability of the results.  
In conclusion, this meta-analysis demonstrates a consistent pattern of decreased FA in the left 
MCP, CC, inferior longitudinal fasciculus, and inferior fronto-occipital fasciculus. In particular, 
FA decreases in the MCP and CC in PD were robustly present in the sensitivity analyses. These 
results suggest that the altered WM microstructures in the MCP and CC may serve as a potential 
neuroimaging biomarker of PD. Furthermore, the subgroup analyses show that medication status, 
analysis approaches and the number of diffusion directions have an important impact on the 
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